Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728857 · ClinicalTrials.gov registry record · NA
Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction
A NA study, sponsored by Zeltiq Aesthetics.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01728857: Completed NA study, sponsored by Zeltiq Aesthetics.
NCT01728857 is a NA study that has completed, run by Zeltiq Aesthetics. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01728857, a NA study, has completed, sponsored by Zeltiq Aesthetics.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
Evaluate the effects of tissue optimization before and during cryolipolysis procedures on the outcome of non-invasive fat reduction using the ZELTIQ System.
Primary Outcome
Photographs of the treatment areas were taken at baseline, and at 16-weeks after the first treatment with the ZELTIQ System were assessed for any visual changes. The photographs were assessed by blinded independent reviewers (IPR) to correctly identify the 16-weeks post-treatment photographs from randomly placed side-by-side comparison of before and after photographs. Reported here is the percentage (%) of images that were correctly identified by at least 2 out of 3 blinded independent reviewers
Interventions
- DEVICE The Zeltiq System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-03-10 |
| Phase | NA |
What the finished NCT01728857 record still lists
NCT01728857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which The Zeltiq System is the first listed.
NCT01728857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01728857 about?
NCT01728857 is a clinical study titled "Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction". Evaluate the effects of tissue optimization before and during cryolipolysis procedures on the outcome of non-invasive fat reduction using the ZELTIQ System.
What is the current status of trial NCT01728857?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2012-11. Estimated completion is 2014-03-10.
What interventions are being tested in trial NCT01728857?
The interventions under investigation include: The Zeltiq System (DEVICE).
Who is sponsoring clinical trial NCT01728857?
This trial is sponsored by Zeltiq Aesthetics, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01728857's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia